Elizabeth Colston

机构：Bristol-Myers Squibb (United States)

发表论文 42 篇 · 总被引 1601 次 · h-index 14

代表论文

• Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial (2022 · Journal of the American Academy of Dermatology · 被引 372)
• Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial (2022 · Journal of the American Academy of Dermatology · 被引 300)
• Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)* (2019 · Critical Care Medicine · 被引 256)
• Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab (2019 · Intensive Care Medicine · 被引 205)
• Soluble receptor‐resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. (1994 · The EMBO Journal · 被引 102)
• Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition (1995 · Journal of Virology · 被引 75)